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N-acetylglucosaminyltransferase V (GnT-V) is an enzyme that catalyses b1–6 branching of N-acetylglucosamine on asparagine-linked
oligosaccharides of cell proteins. The present study aimed to investigate GnT-V expression and its prognostic significance in
endometrial cancer. N-acetylglucosaminyltransferase V expression was studied by immunohistochemistry in 74 surgically resected
endometrial cancers, and the staining intensity was evaluated. High GnT-V expression in tumour cells was found in 43 (58.1%) of the
74 cases, and was positively correlated with advanced patient age, histological grade, and lymph vascular space involvement. Patients
with high GnT-V expression had significantly impaired overall survival and progression-free survival (PFS) (P¼0.0041 and P¼0.0023,
respectively) compared to patients with low expression of GnT-V. On multivariate analysis, GnT-V expression was an independent
prognostic factor for PFS (P¼0.0364). b1–6 branching of asparagine-linked oligosaccharides was also detected in GnT-V-positive
endometrial cancer cells by leukoagglutinating phytohaemagglutinin (L4-PHA) staining, and the molecular size of the major
glycoproteins recognised by L4-PHA was approximately 60–200kDa by lectin blot analysis. These results suggested that high GnT-V
expression was correlated with an unfavourable clinical outcome, and that GnT-V is involved in the malignant potential of
endometrial cancer by increasing the synthesis of b1–6 branching of asparagine-linked oligosaccharides.
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The glycosylation of cell-surface glycoproteins is widely accepted
to play a key role in a variety of specific biological interactions
(Hakomori, 1989). In particular, branching of asparagine-linked
oligosaccharides is shown to regulate metastatic potential in cancer
cells (Pierce et al, 1997). Among the several patterns of branching,
b1–6 branching of N-acetylglucosamine to a-D-6 mannnoside
enhances metastasis in experimental cancer models of mice
(Dennis et al, 1987). N-acetylglucosaminyltransferase V (GnT-V,
EC 4.1.15) catalyses this branching and is most strongly linked to
tumour invasion and metastasis. In human cancers, several studies
have shown that high activity or expression of GnT-V was
associated with poor prognosis in human colorectal cancer
(Murata et al, 2000) and breast cancer (Fernandes et al, 1991).
On the other hand, GnT-V is expressed in normal human lung and
low expression of GnT-V in non-small cell lung cancer is
associated with poor prognosis (Dosaka-Akita et al, 2004). Thus,
GnT-V expression and its functional and prognostic significance in
human cancer remain controversial.
Endometrial cancer is currently the most common gynaecologic
malignancy in industrialised countries (Amant et al, 2005).
Although this neoplasm is generally considered non-aggressive,
it is a heterogeneous disease with 5-year survival rates ranging
from over 80–90% for women with clinical stage I disease
(Creutzberg et al, 2004). Currently, various clinicopathologic
parameters are used to predict the outcome of the disease and to
decide the need for adjuvant treatment: surgical stage, histological
type, grade, depth of myometrial invasion, cervical stromal
invasion, lymph node metastasis, lymph vascular involvement,
and peritoneal cytology (Morrow et al, 1991; Grigsby et al, 1992);
however, the majority of parameters have been criticised for their
subjectivity and poor reproducibility (Nordstrom et al, 1996).
Thus, in addition to the conventional clinicopathological para-
meters, the identification of biochemical or molecular markers
more strictly related to the intrinsic biological behaviour of
endometrial cancer, and the individualisation of adjuvant therapy
based on more reliable prognostic indicators, may be helpful to
further improve the survival of patients, as well as to prevent the
unnecessary use of adjuvant therapy.
In the present study, we examined GnT-V expression by
immunohistochemistry in surgically resected endometrial cancer
and analysed its biological and clinical importance, especially as a
potential prognostic factor.
MATERIALS AND METHODS
Patients and tissue specimens
Seventy-four patients with endometrial endometrioid adenocarci-
noma between 1990 and 2005 were included in this study. Initial
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sdiagnoses were made preoperatively by the pathological review of
endometrial biopsy or curettage specimens. Surgical treatment
consisted of total abdominal hysterectomy and bilateral salpin-
gooophorectomy, followed by surgical staging, including perito-
neal washing cytology and lymphadenectomy. Patients with
histological cell types other than endometrioid adenocarcinoma,
such as papillary serous or clear cell, were not included in this
study. The mean age of the patients was 58.3 years (range: 38–86).
All patients were staged according to the 1988 International
Federation of Gynecology and Obstetrics (FIGO) criteria: 43 were
stage I (four were IA, 29 were IB, 10 were IC), nine were stage II, 17
were stage III, and five were stage IV. Histological grade was
assigned according to the criteria of the World Health Organisa-
tion (WHO) classification: 28 were G1 (well differentiated), 33 were
G2 (moderately differentiated), and 13 were G3 (poorly differ-
entiated). In this study, all patients with FIGO stage IC and more
advanced-stage disease received post-operative adjuvant chemo-
therapy with six cycles of cisplatin/doxorubicin/cyclophosphamide
or cisplatin plus etoposide in 1992–1999, and carboplatin plus
paclitaxel after 2000. Patients receiving post-operative radiation
therapy or any preoperative treatment were excluded from this
study because the number of patients was very small. Tumour
recurrence/progression was defined based on clinical, radiological,
or histological diagnosis. Patients with recurrence were treated
with chemotherapy, local radiation therapy, or surgical tumour
resection if possible.
Western blot analysis
JAR human choriocarcinoma cells were obtained from American
Type Culture Collection (ATCC, Manassas, VA, USA) and UtSMC
normal human uterine smooth muscle cell line (CC-2562) from
Cambrex (Walkersville, MD, USA). Tumour tissue samples and
cells were homogenised in a lysis buffer consisting of a protease
inhibitor mixture in radioimmunoprecipitation assay buffer. After
centrifugation at 15000g for 20min, the supernatant was obtained.
Twenty micrograms of protein extract was separated by SDS 10%
polyacrylamide gel electrophoresis, transferred onto a nitrocellu-
lose membrane, and immunoblotted with anti-GnT-V monoclonal
antibody (24D11) (Nakahara et al, 2003) at a dilution of 1:1000.
Immunoreactive proteins were stained using a chemiluminescence
detection system (ECL, GE Healthcare, Buckinghamshire, UK).
Leukoagglutinating phytohaemagglutinin blot analysis
Protein-blotted nitrocellulose filters were prepared in exactly the
same way as described for Western blotting. After blocking with
5% skim milk for 30min at room temperature, the filter was
incubated in PBS containing 1:1000 diluted biotinylated leuko-
agglutinating phytohaemagglutinin (L4-PHA, Seikagaku, Tokyo,
Japan), which preferentially recognises b1–6 branches of tri- or
tetra-antennary sugar chains, for 1h at room temperature. The
filter was washed three times with PBS containing 0.05% Tween 20
(TPBS) for 10min each. Substrate binding was detected with a
1:1000 dilution of avidin–peroxidase conjugate (ABC kit, Vector
Res., CA, USA) in TPBS for 30min at room temperature. The
membrane was washed and then developed using ECL reagents
(GE Healthcare, Buckinghamshire, UK).
Lectin blot analysis on immunoprecipitated b1 integrin
For immunoprecipitation, 800mg of proteins were extracted from
each sample tissue. After incubation with 1ml of anti-human b1
integrin mAb MAB2247 (Chemicon International Inc., Temecula,
CA, USA) overnight at 41C, immune complexes were collected
with 30ml of protein G-Sepharose 4EF beads (GE Healthcare,
Buckinghamshire, UK). The complexes were released by boiling
in sampling buffer without a detergent, separated by 7.5%
SDS–PAGE. The membrane filter was analysed by L4-PHA lectin
blot, as described above. After deprobing and blocking, it was
subjected to Western blot analysis using anti-b1 integrin mAb as
described above.
Immunohistochemistry for GnT-V
Informed consent was obtained from individual patients for the
use of their tissue samples. A mouse monoclonal antibody against
recombinant human GnT-V was made according to the standard
protocol, as described previously (Murata et al, 2000). Briefly, mice
were immunised by recombinant GnT-V, and monoclonal anti-
bodies for GnT-V were screened by the availability for immuno-
histochemistry. The antibody used in the present study recognised
545SKNTDFFIGKPTILRELTS
562 of the human GnT-V amino-acid
sequence and gave the best signal for immunohistochemistry.
Surgical specimens were fixed in 10% formalin and embedded in
paraffin. Paraffin specimens were cut at a thickness of 4mm. For
heat-induced epitope retrieval, deparaffinised sections were soaked
in Target Retrieval Solution consisting of 10mM Tris and 1mM
EDTA (DAKO, Glostrup, Denmark), and treated at 951C for 30min
in a microwave oven. Immunohistochemical staining was
performed using the avidin–biotin immunoperoxidase technique
(Histofine SAB-PO kit, Nichirei, Tokyo, Japan). Endogenous
peroxidase activity was blocked by incubation with 0.3% H2O2 in
methanol for 15min, and nonspecific immunoglobulin binding
was blocked by incubation with 10% normal goat serum for
10min. Sections were incubated at 41C overnight with anti-GnT-V
antibody at 1:400 dilution or antiproliferating cell nuclear antigen
(PCNA) antibody (DAKO) at 1:30. The sections were rinsed and
incubated for 30min with the biotinylated second antibody. After
washing, the sections were incubated for 5min with horseradish
peroxidase-conjugated streptavidin, and finally treated with 3,30-
diaminobenzidine tetrahydrochloride (Nichirei, Tokyo, Japan) in
0.01% H2O2 for 3min. The slides were counterstained with Meyer’s
haematoxylin. As a negative control, the primary antibody was
replaced with normal mouse IgG at an appropriate dilution. As a
positive control, tissue sections of normal placenta were used as
reported previously (Tomiie et al, 2005). N-acetylglucosaminyl-
transferase V expression levels were classified semiquantitatively
based on the total scores of the per cent positivity of stained
tumour cells and the staining intensity. Namely, the per cent
positivity was scored as ‘0’ if o5% (negative), ‘1’ if 5–30%
(sporadic), ‘2’ if 30–70% (focal), and ‘3’ if 470% (diffuse) of cells
stained, whereas staining intensity was scored relative to the
known positive and negative controls as ‘0’ if no staining, ‘1’ if
weakly stained, ‘2’ if moderately stained (intermediate level
between strong and weak), and ‘3’ if strongly stained. The final
GnT-V expression score was defined as follows: ‘GnT-V low’ if the
sum of the per cent positivity score and the staining intensity score
was 0–4 and ‘GnT-V high’ if the sum was 5–6. In each case, at
least three different areas were evaluated. The scoring procedure
was carried out twice by two independent observers without any
knowledge of the clinical data. The concordance rate was over 95%
between the observers. In case of disagreement, the slides were
reviewed simultaneously by these two observers, together with
another observer, who were seated together at a multiheaded
microscope, to resolve the difference of opinion.
Leukoagglutinating phytohaemagglutinin histochemistry
The expression of b1–6 branching asparagine-linked oligosac-
charides was analysed by L4-PHA histochemistry, with a modified
previous method (Suzuki et al, 1999). Briefly, after deparaffinisa-
tion, trypsinisation was performed in Tris buffer containing 0.1%
trypsin (Difco Laboratories, Detroit, MI, USA) and 0.1% CaCl2 for
10min at 371C after blocking endogenous peroxidase activity. The
sections were incubated with 5% skim milk in PBS for 20min at
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sroom temperature to block nonspecific staining. The sections were
incubated with HRP-PHA-L4 (Seikagaku) at a dilution of 1:200 at
41C overnight. Staining was performed by the biotin–streptavidin
peroxidase method with 3,30-diaminobenzidine as a chromogen.
Haematoxylin was used as a counterstain.
Statistical analysis
Statistical analysis was performed using w
2 for the independence
test, Fisher’s exact probability test, or Student’s t-test. For survival
analysis, the Kaplan–Meier method was applied, and statistical
significance was calculated using the log-rank test. Cox propor-
tional-hazard analysis was used for univariate and multivariate
analyses to explore the effect of variables on survival. StatView
software ver.5.0 (SAS Institute Inc., Cary, NC, USA) was used for
statistical analyses, and a P-value of o0.05 was considered
significant.
RESULTS
GnT-V protein expression and lectin blot analysis in
endometrial cancer tissue
First, the GnT-V protein expression was examined in endometrial
cancer tissues obtained from seven patients using Western blot
analysis. In all samples, GnT-V protein was detected as
approximately 110kDa bands, although its expression level varied
among the samples (Figure 1A). The broad bands of GnT-V may
be due to oligosaccharide modification of GnT-V, because GnT-V
has as many as five sugar chains and the molecular weight of
GnT-V is smaller with less b1–6GlcNAc branching (Nakahara
et al, 2003).
To evaluate the level of b1–6 branching, we also performed
lectin blot analysis on total cellular proteins using L4-PHA, which
preferentially binds to GlcNAc residues on b1–6 branches of tri-
or tetra-antennary sugar chains (Figure 1B). This analysis showed
that GnT-V certainly catalysed such specific glycosylation to target
glycoproteins, whose major molecular sizes were approximately
60–200kDa.
Lectin blot analysis on immunoprecipitated b1 integrin
It has been reported that b1 integrin is a target molecule of GnT-V
in certain cell lines (Guo et al, 2002; Nakahara et al, 2003);
therefore, to investigate the glycosylation state of b1 integrin, we
performed L4-PHA blot analysis on immunoprecipitated b1
integrin. The results showed that b1 integrin, which had been
immunoprecipitated from endometrial cancer tissues, certainly
contained b1–6 GlcNAc branching (Figure 1C), suggesting that b1
integrin is a target substrate of GnT-V in endometrial cancers.
Immunohistochemical expression of GnT-V and L4-PHA
staining in endometrial cancer tissues
We examined GnT-V expression in endometrial cancer tissues by
immunohistochemical staining using 74 surgical specimens. As
shown in Figure 2A–C, GnT-V immunoreactivity was detected at
variable levels, and was found in the cytoplasm of cancer cells,
which were identified using PCNA co-staining (Figure 2G–I). In
contrast, GnT-V immunoreactivity was very faint or absent in
tumour stroma (Figure 2A–C) and normal endometrium
(Figure 2J). N-acetylglucosaminyltransferase V immunoreactivity
was not detected in the negative control experiment (Figure 2L),
whereas it was strongly detected in placental tissues used as a
positive control (Figure 2K). Next, we examined the expression of
b1–6 branching asparagine-linked oligosaccharides by L4-PHA
histochemistry in the same sections, simultaneously. Leukoagglu-
tinating phytohaemagglutinin staining was very weak in tumour
cells that showed weak GnT-V immunostaining (Figure 2D), while
it was moderate-to-strong in cancer cells that showed high GnT-V
immunostaining (Figure 2E and F). These results were consistent
with the results of lectin blotting, which recognised b1–6
branching in endometrial cancer with variable intensity.
Correlation of GnT-V expression with clinicopathological
parameters
Of the 74 specimens examined, ‘low GnT-V expression’ tumours
were found in 31 (41.9%) cases, and ‘high GnT-V expression’ in 43
(58.1%) cases, respectively. The correlations of high GnT-V
expression with various clinicopathological parameters in the 74
cases are summarised in Table 1. High GnT-V expression was
positively correlated with age (P¼0.045), histological grade
(P¼0.011), and lymph vascular space involvement (Po0.001),
but not with the FIGO surgical stage, lymph node metastasis, and
myometrial invasion.
Correlation of GnT-V expression with patient survival
Follow-up data were available for all 74 patients and the median
follow-up period was 72.9 months (range: 3–160). During the
follow-up period, disease progression/recurrence was observed in
20 patients (27.0%), of which 12 (16.2%) died. The median time
to progression/recurrence and death was 15.0 and 28.5 months,
115 kDa
G1 G2 G3
GnT-V 180
115
82
64
49
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26
(kDa) 1234567 P 1234567
β-Actin
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Figure 1 GnT-V and b1–6 branching glycoprotein expression, and b1–6GlcNAc branching of b1 integrin in endometrial cancer tissues. (A) Western
blot analysis with anti-GnT-V mAb. (B) Lectin blot analysis with L4-PHA. Lanes 1–7 corresponded to seven different endometrial cancer patients (G1, grade
1; G2, grade 2; G3, grade 3). P, JAR is a choriocarcinoma cell line used as a positive control for GnT-V expression; N, normal human uterine smooth muscle
cells (UtSMC) as a negative control. (C) b1 integrin was immunoprecipitated from endometrial cancer tissues from three different patients. The amount of
b1–6GlcNAc branching of b1 integrin was analysed by means of an L4-PHA lectin blot (upper panel). The membrane was reprobed with a specific mAb to
b1 integrin (lower panel).
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srespectively. To evaluate the impact of GnT-V expression on
patient prognosis, overall survival (OS) and progression-free
survival (PFS) curves were constructed using the Kaplan–Meier
method. The OS rates of patients with GnT-V low and GnT-V high
were 96.8 and 74.4%, respectively (Figure 3A). The 5-year PFS rates
for GnT-V low and GnT-V high were 90.3 and 60.5%, respectively
(Figure 3B). Patients with high GnT-V expression had significantly
impaired OS (P¼0.0041) and PFS (P¼0.0023) as compared to
patients with low expression of GnT-V (Figure 3A and B).
Multivariate analysis of prognostic variables in
endometrial cancer patients
Cox proportional-hazard analysis was performed to compare the
impact of GnT-V expression on survival with currently used
clinicopathological prognostic factors. The results of univariate/
multivariate analyses of the variables, including GnT-V expression,
age, surgical stage, grade, lymph vascular space involvement, node
status, and myometrial invasion, with respect to OS and PFS, are
shown in Tables 2 and 3, respectively. Among the seven variables,
there was no significant prognostic factor with respect to OS on
multivariate analysis, although the surgical stage, lymph vascular
invasion, node status, myometrial invasion, and GnT-V expression
were significant prognostic factors on univariate analysis (Table 2).
In contrast, only GnT-V expression was found to be an
independent prognostic factor (hazard ratio¼4.164, P¼0.0364)
with respect to PFS on multivariate analysis (Table 3).
DISCUSSION
In the present study, we demonstrated the expression of GnT-V in
endometrial cancer using 74 surgical specimens, and found that
ABC
GH I
DEF
L JK
Figure 2 Immunohistochemical staining patterns for GnT-V and staining of L4-PHA in endometrial cancers. Staining pattern of a tumour: (A) GnT-V low;
(B and C) GnT-V high. (D–F)L 4-PHA staining and (G–I) PCNA immunostaining were performed simultaneously with the same A, B, and C specimens,
respectively. (J) Normal endometrial cells showed very faint or negative GnT-V expression. (K) Positive control for GnT-V (normal placenta). (L) Negative
control. Original magnification,  100.
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shigh GnT-V expression by tumour cells was positively correlated
with impaired clinical outcome. The immunoreactivity of GnT-V
was very weak in normal endometrium and increased clearly in
endometrial cancer. Oligosaccharides on glycoproteins are altered
in tumorigenesis and often play a role in the regulation of the
biological characteristics of tumours (Hakomori, 1989). Each
oligosaccharide is synthesised by a specific glycosyltransferase
whose expression affects a specific function of glycoprotein
through glycosylation in normal and malignant cells (Varki,
1993). Among many glycosyltransferases and oligosaccharides,
GnT-V and its products, b1–6 branching N-linked oligosaccha-
rides, have been associated with the malignant potential of
cancer (Dennis et al, 1987). In colon cancer, breast cancer, and
oesophageal cancer, GnT-V expression has a positive correlation
with poor prognosis, which is consistent with our results in the
present study (Fernandes et al, 1991; Murata et al, 2000; Ishibashi
et al, 2005). On the other hand, low GnT-V expression is associated
with shorter survival and poor prognosis in non-small cell lung
cancer, bladder cancer, and hepatocellular cancer (Ito et al, 2001;
Dosaka-Akita et al, 2004; Ishimura et al, 2006). It may depend on
the type of cancer or originating tissues whether GnT-V expression
is associated positively with poor prognosis.
We confirmed the levels of b1–6 branching in endometrial
cancers using lectin blotting and L4-PHA histochemistry.
N-acetylglucosaminyltransferase V expression is not equal to the
expression of b1–6 branching asparagine-linked oligosaccharides
analysed by L4-PHA histochemistry (Dosaka-Akita et al, 2004).
This is because GnT-V has been shown to function as an inducer of
angiogenesis (Saito et al, 2002), which is completely different from
the original function of glycosyltransferase, and GnT-V expression
does not necessarily result in the synthesis of b1–6 branching
oligosaccharides. Our results showed that GnT-V-expression
intensity was well consistent with L4-PHA-staining intensity in
tumour cells. These findings suggested that GnT-V plays a
functional role in the malignant potential of endometrial cancer
cells by the synthesis of b1–6 branching oligosaccharides.
Our lectin blotting revealed that major target glycoproteins of
GnT-V in endometrial cancer were 60–200kDa in molecular size.
Previous reports indicated several specific substrates for GnT-V
glycosylation and changes in the biological characteristics of
cancer cells. An increased level of b1–6 branching on b1 integrin,
a 130kDa subunit of fibronectin receptor, by GnT-V resulted in the
inhibition of cisplatin-induced apoptosis, or inhibition of cluster-
ing of a5b1 integrin and promotion of cell migration in neck
squamous cell carcinoma and fibrosarcoma (Guo et al, 2002;
Nakahara et al, 2003). Lamp-1 is a 90–120kDa molecule expressed
on cell and lysosome membranes, and plays an important role in
lysosomal trafficking, matrix degradation, and cell adhesion.
N-acetylglucosaminyltransferase V glycosylation of lamp-1 inhibits
its degradation, and the stabilisation of lamp-1 results in increased
extracellular matrix degradation (Fukuda, 1991; Kundra and
Kornfeld, 1999). Matriptase is an 80kDa serine protease involved
in cancer metastasis by the activation of urokinase-type plasmino-
gen activator (u-PA) and hepatocyte growth factor (Lee et al,
2000). The addition of b1–6 branching on matriptase by GnT-V
inhibits its degradation, resulting in the upregulation of matriptase
expression in gastric cancer (Ihara et al, 2002). Of those molecules,
matriptase and b1 integrin were expressed in endometrial cancer,
especially b1 integrin with b1–6 branching by GnT-V (Figure 1C).
Increased GnT-V did not change the expression of a5b1 integrin,
but increased the level of b1–6 branching on it, and subsequently
inhibited integrin clustering and signal transduction pathways. As
a result, cell migration and invasion were stimulated (Guo et al,
2002; Nakahara et al, 2006). In the present study, we showed that
high GnT-V expression was significantly correlated with lymph
vascular invasion and the histological grade. These results
suggested that GnT-V might be involved in tumour cell migration
or invasion by the modification of oligosaccharides of b1 integrin
Table 1 Correlation of GnT-V expression with clinicopathological
factors in endometrial cancer
GnT-V expression
Characteristics Patient no. Low High P-value
a
All cases 74 31 (41.9%) 43 (58.1%)
Age
p60 45 23 (51.1%) 22 (48.9%) 0.045
460 29 8 (27.6%) 21 (72.4%)
FIGO surgical stage
I+II 52 25 (48.1%) 27 (51.9%) 0.097
III+IV 22 6 (27.3%) 16 (72.3%)
Histological grading
G1 28 17 (60.7%) 11 (39.3%) 0.011
G2/G3 46 14 (30.4%) 32 (69.6%)
Lymph vascular invasion
Negative 40 24 (60.0%) 16 (40.0%) o0.001
Positive 34 7 (20.6%) 27 (79.4%)
Nodal status
N0 60 27 (45.0%) 33 (55.0%) 0.262
N1 14 4 (28.6%) 10 (71.4%)
Myometrial invasion
1/24 43 20 (46.5%) 23 (53.5%) 0.343
1/2p 31 11 (35.5%) 20 (64.5%)
Abbreviations: FIGO¼International Federation of Gynecology and Obstetrics;
GnT-V¼N-acetylglucosaminyltransferase V.
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Figure 3 Overall survival (OS) and progression-free survival (PFS) curve
drawn using the Kaplan–Meier method according to GnT-V expression in
endometrial cancer patients. OS (A) and PFS (B) in all patients (n¼74).
Significant differences in OS (P¼0.0041), and PFS (P¼0.0023).
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sin endometrial cancer, resulting in disease progression and poor
prognosis. In addition, GnT-V might be linked to malignant
potential, increasing b1–6 branching synthesis in poorly differ-
entiated cancer cells; however, the functional significance of GnT-
V expression in endometrial cancer has to be studied further.
In conclusion, we demonstrated that high GnT-V expression
correlated with impaired clinical outcome in endometrial cancer
patients. Furthermore, GnT-V was an independent prognostic
factor for PFS. These results indicate that GnT-V is a reliable and
promising prognostic indicator and might become a novel
molecular target in the strategy for the treatment of endometrial
cancer.
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